Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) will report first quarter 2026 financial results and provide a business update via live webcast on Thursday, April 30, 2026 at 8:00 am EDT.

A recording will be available for 90 days. Phathom commercializes vonoprazan as VOQUEZNA products for GERD and H. pylori in the U.S. More information is on the Events & Presentations section of the company website.

AI-generated analysis. Not financial advice.

News Market Reaction – PHAT

+2.12%

13 alerts

+2.12% News Effect

-3.2% Trough in 2 hr 1 min

+$21M Valuation Impact

$1.03B Market Cap

0.6x Rel. Volume

On the day this news was published, PHAT gained 2.12%, reflecting a moderate positive market reaction. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $21M to the company's valuation, bringing the market cap to $1.03B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings call date: April 30, 2026 Earnings call time: 8:00 am EDT Recording availability: 90 days

3 metrics

Earnings call date April 30, 2026 First quarter 2026 results webcast

Earnings call time 8:00 am EDT First quarter 2026 webcast start time

Recording availability 90 days Length of post-call webcast access

Market Reality Check

Price: $11.87 Vol: Volume 920,512 vs 20-day ...

normal vol

$11.87 Last Close

Volume Volume 920,512 vs 20-day average 1,085,503 (relative volume 0.85x). normal

Technical Price $13.19 is trading above 200-day MA at $12.41 and 27.96% below 52-week high of $18.31.

Peers on Argus

PHAT is up 4.6% with mixed peer moves: IMNM +3.27%, PRAX +4.98%, QURE +3.11%, UR...

PHAT is up 4.6% with mixed peer moves: IMNM +3.27%, PRAX +4.98%, QURE +3.11%, URGN +2.36%, while EYPT is down 0.47%, suggesting a mainly stock-specific reaction.

Previous Earnings date Reports

1 past event · Latest: Feb 17 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Earnings date announcement	Neutral	+6.2%	Set date for Q4 and full-year 2025 results with webcast details.

Pattern Detected

Prior earnings date scheduling news coincided with a positive price move.

Recent Company History

Recent news shows PHAT emphasizing investor communication and strong growth. An earlier earnings date announcement on Feb 17, 2026 preceded a 6.16% gain into the fourth-quarter and full-year 2025 report. Subsequent filings, including the 10-K and 8-K on Feb 26, highlighted VOQUEZNA-driven revenue growth and a path toward profitability. Today’s first-quarter 2026 earnings date notice continues this cadence of regular financial updates to the market.

Historical Comparison

+6.2% avg move · In past earnings date announcements, PHAT saw an average move of 6.16%, indicating this type of sche...

earnings date

+6.2%

Average Historical Move earnings date

In past earnings date announcements, PHAT saw an average move of 6.16%, indicating this type of scheduling news has previously drawn clear market attention.

The company has maintained a consistent pattern of pre-announcing earnings dates with webcast access details, reinforcing transparency around quarterly and annual financial updates.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-01-07

An effective Form S-3ASR automatic shelf filed on Jan 7, 2026 allows Phathom to offer common stock, preferred stock, debt securities, warrants and units via future prospectus supplements. In addition, 5,827,415 shares of common stock were registered for potential resale by a large stockholder, with proceeds from those resales going to the holder rather than the company.

Market Pulse Summary

This announcement sets the schedule for first quarter 2026 results, with a webcast on April 30, 2026...

Analysis

This announcement sets the schedule for first quarter 2026 results, with a webcast on April 30, 2026 at 8:00 am EDT and a replay available for 90 days. It continues Phathom’s pattern of clearly pre-announcing earnings events. Investors may focus on how upcoming results compare with prior guidance and the company’s progress in commercializing VOQUEZNA, while also monitoring any use of its automatic shelf registration for future financing.

Key Terms

biopharmaceutical, gastrointestinal (GI) diseases, potassium-competitive acid blocker (PCAB), non-erosive GERD, +2 more

6 terms

biopharmaceutical medical

"Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing..."

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

gastrointestinal (GI) diseases medical

"novel treatments for gastrointestinal (GI) diseases, today announced that it will host..."

Gastrointestinal (GI) diseases are illnesses that affect the digestive tract—from the mouth and esophagus down through the stomach, intestines, and related organs like the liver and pancreas. For investors this matters because GI conditions drive demand for diagnostics, medications, procedures and long-term care, similar to how a clogged plumbing system demands repairs and ongoing maintenance; changes in treatment options, regulation or prevalence can significantly affect healthcare revenue and drug development prospects.

potassium-competitive acid blocker (PCAB) medical

"vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe..."

A potassium-competitive acid blocker (PCAB) is a type of medicine that reduces stomach acid by directly blocking the pump that produces acid, often acting faster and more strongly than older acid-reducing drugs. For investors, PCABs matter because they represent a newer therapeutic option with potential for strong sales, patent protection, pricing power and regulatory milestones—factors that can affect a drugmaker’s revenue and competitive position much like a faster, more efficient faucet valve changes water flow compared with an older valve.

non-erosive GERD medical

"for the relief of heartburn associated with Non-Erosive GERD in adults, the healing..."

Non-erosive GERD is a form of acid reflux where people experience typical symptoms such as heartburn and regurgitation but endoscopic exams show no visible injury to the lining of the esophagus. Think of it like a smoke alarm going off without any visible fire — the problem causes discomfort but isn’t showing obvious tissue damage. It matters to investors because this subtype often responds differently to treatments, affects trial design and patient selection, and represents a large patient group that shapes market size, pricing and reimbursement for therapies.

erosive GERD medical

"the healing and maintenance of healing of Erosive GERD in adults and relief..."

Erosive GERD is a form of acid reflux where stomach acid not only flows back into the food pipe but actually damages its lining, creating visible sores or erosion. Investors should care because this more severe, measurable form of reflux generally requires stronger or long‑term treatments, drives demand for prescription drugs, medical procedures and diagnostics, and is a common clinical endpoint in regulator and payer decisions that affect company revenues.

H. pylori infection medical

"and VOQUEZNA DUAL PAK for the treatment of H. pylori infection in adults."

H. pylori infection is an infection of the stomach lining caused by the bacterium Helicobacter pylori that can cause chronic stomach inflammation, ulcers, and raise the long‑term risk of stomach cancer. For investors it matters because diagnosis, treatment, and prevention drive demand for drugs, diagnostics and medical procedures, influence clinical trial outcomes and regulatory decisions, and can affect sales and valuation in healthcare and consumer health businesses — similar to how a persistent pest can change maintenance and replacement needs for a property.

AI-generated analysis. Not financial advice.

• Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT
  

FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

When will Phathom Pharmaceuticals (PHAT) report Q1 2026 results and how can I join the webcast?

Phathom will report Q1 2026 results on April 30, 2026 at 8:00 am EDT, via a live webcast. According to the company, the webcast and presentation materials will be accessible in the Events & Presentations section of the Phathom investor website.

Will the Phathom (PHAT) Q1 2026 webcast be available after the live call?

Yes. A recording of the webcast will be available for 90 days after the call. According to the company, investors can access the archived recording on the Phathom investor website's Events & Presentations page.

What topics will Phathom (PHAT) cover during the April 30, 2026 business update?

The webcast will cover first quarter 2026 financial results and a business update. According to the company, management will discuss performance, commercial activities, and developments related to vonoprazan and VOQUEZNA products.

What VOQUEZNA products does Phathom (PHAT) market in the United States?

Phathom markets VOQUEZNA tablets, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK in the U.S. According to the company, these products treat GERD-related heartburn and H. pylori infection in adults using vonoprazan-based regimens.

Where can investors find Phathom (PHAT) investor contacts and media information?

Investor and media contacts are listed on Phathom's website and in the announcement. According to the company, media inquiries go to media@phathompharma.com and investor questions to ir@phathompharma.com with phone support available.

Which regions does Phathom (PHAT) hold exclusive rights to vonoprazan for commercialization?

Phathom holds in-licensed exclusive rights to vonoprazan for the U.S., Europe, and Canada. According to the company, these rights support its commercialization strategy for VOQUEZNA products across those regions.